FDA grants fast track designation for retinitis pigmentosa treatment
EA-2353 for the treatment of retinitis pigmentosa received fast-track designation from the FDA, according to a press release from Endogena Therapeutics. The gene-independent treatment approach activates endogenous retinal stem and progenitor…